Biomolecules & Therapeutics

The Korean Society of Applied Pharmacology (한국응용약물학회)
권호 표지

Acute Toxicity of CKD-602, a New Anticancer Agent, in Rats

  • Published : 2004.03.01
Download PDF
⟨ Previous Next ⟩

Abstract

The present study was carried out to investigate the potential acute toxicity of CKD-602 by a single intravenous dose in Sprague-Dawley rats. Ten males females were used in each test groups: a vehicle control, 34.7, 4l.7, 50.0, 60.0 and 72.0 mg/kg groups, and were given different single intravenous doses of CKD-602 to the test animals. Mortalities, clinical findings, and body weight changes were monitored for the 14-day period following the administration. At the end of l4-day observation period, all animals were sacrificed and complete gross postmortem examinations were performed. One, 1, 2, 8 and 9 cases of deaths occurred in the male dose groups of 34.7, 41.7, 50.0, 60.0 and 72.0 mg/kg, respectively, and 1, 5 and 9 cases in the female dose groups 50.0, 60.0 and 72.0 mg/kg, respectively. An increase in the incidence of clinical signs such as alopecia, skin pallor skin ulcerations, emaciation and change of fecal material was found in the both sexes of all treatment groups. A decrease or Suppression in the body weight was also observed in a dose-dependent manner. In autopsy, male and/or female rats of the treatment groups showed treatment-related gross findings such as splenomegaly, atrophy of the testis, epididymis, seminal vesicles, ovary, uterus and thymus which were dose-dependent in incidence and severity. Based on these results, it was concluded that a single intravenous injection of CKD-602 to rats caused significant toxicities in gastrointestinal, hematopoietic, and reproductive systems. The $LD_{50}$ value was 53.8 (95% confidence limit: 48.5~60.6) mg/kg for males and 60.l (95% confidence limit: 55.3~65.8) mg/kg for females. The $LD_{10}$ value was 39.9 (95% confidence limit: 3l.7~44.8) mg/kg for males and 50.3 (95% confidence limit: 40.6~54.8) mg/kg for females.

Keywords

References

  1. Bleiberg, H. and Rothenberg, M. L. (1996). CPT-11: From DNA topology to clinical activity. Semi. Oncol., 23, I-50
  2. Chatelut, E., Delord, J. P. and Canal, P. (2003). Toxicity patterns of cytotoxic drugs. Invest. New Drugs, 21, 141-148 https://doi.org/10.1023/A:1023565227808
  3. Dahut, W., Harolod, N., Takimototo, C., Allegra, C., Chen, A., Hamilton, J. M., Arbuck, S., Sorensen, M., Grollman, F., Nakashima, H., Lieberman, R., Liang, M., Corse, W. and Grem, J. (1996): Phase I and pharmacokinetic study of 9-aminocamptothecin given as a 72-hour infusion in adult cancer patients. J. Clin. Oncol., 14, 1236-1244 https://doi.org/10.1200/JCO.1996.14.4.1236
  4. Gottlieb, J. A., Guarino, A. M., Call, J. B., Oliverio, V. T. and Block, J. B. (1970). Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC 100880). Cancer Chemother. Rep., 54, 461-470
  5. Hashimoto, H., Chatterjee, S. and Berger, N.A. (1995). Mutagenic activity of topoisomerase I inhibitors. Clin. Cancer Res., 1, 369-376
  6. Hertzberg, R. P., Caranfa, M. J., Holden, K. G., Jakas, D. R, Gallagher, G., Mattern, M. R., Mong, S. M., Bartus, J. O., Johnson, R. K. and Kingsbury, W. D. (1989). Modification of the hydroxy lactone ring of camptothecin: Inhibition of mammalian topoisomerase I and biological activity. J. Med. Chem., 32,715-720 https://doi.org/10.1021/jm00123a038
  7. Kim, J. H., Lee, S. K., Lim, J. L., Shin, H. J. and Hong, C. I. (2002): Preformulation studies of a novel camptothecin anticancer agent, CKD-602: physicochemical characterization and hydrolytic equilibrium kinetics. Int. J. Pharm., 239, 207-211 https://doi.org/10.1016/S0378-5173(02)00099-6
  8. Kim, E. J., Lee, R. K., Suh, J. E., Han, S. S. and Kim, J. K. (2003a). Safety pharmacology of CKD-602, a novel anticancer agent. Arzneimittel forschung, 53, 272-279
  9. Kim, J. C.; Kim, K. H. and Chung, M. K. (1999): Testicular cytotoxicity of DA -125, a new anthracycline anticancer agent, in rats. Reprod. Toxicol., 13, 391-397 https://doi.org/10.1016/S0890-6238(99)00028-3
  10. Kim, J. C., Kim, S. H., Shin, D. H., Ahn, T. H., Kim, H. C., Kim, Y. B., Jiang, C. Z., Han, J. and Chung, M. K. (2004). Effects of prenatal exposure to the environmental pollutant 2-bromopropane on embryo-fetal development in rats. Toxicology, 196, 77-86 https://doi.org/10.1016/j.tox.2003.11.006
  11. Kim, J. C., Shin, D. H., Ahn, T. H., Kang, S. S., Song, S. W., Han, J., Kim, C. Y., Ha, C. S. and Chung, M. K. (2003b). 26-Week repeated oral dose toxicity study of the new quinolone antibacterial DW-116 in Sprague-Dawley rats. Food Chem. Toxicol., 41, 637-645 https://doi.org/10.1016/S0278-6915(02)00325-3
  12. Kolimannsberger, C., Mross, K., Jakob, A., Kanz, L. and Bokemyer, C. (1999). Topotecan - A novel topoisomerase I inhibitor: Pharmacology and clinical experience. Oncology, 56, 1-12 https://doi.org/10.1159/000011923
  13. Lee, J. H., Lee, J. M., Kim, J. K., Ahn, S. K., Lee, S. J., Kim, M. Y., Jew, S. S., Park, J. G. and Hong, C. I. (1998). Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)- camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor. Arch. Pharm. Res., 21, 581-590 https://doi.org/10.1007/BF02975379
  14. Lee, J. H., Lee, J. M., Lim, K. H., Kim, J. K., Ahn, S. K., Bang, Y. J. and Hong, C. I. (2000). Preclinical and phase I clinical studies with CKD-602, a novel camptothecin derivativ. Ann. N. Y. Acad. Sci., 922, 324-325
  15. Moertel, C. G., Schutt, A. J., Reitmeier, R. J. and Hahn, R. G. (1972). Phase II study of camptothecin (NSC 100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother. Rep., 56, 95-101
  16. Pizzolato, J. F. and Saltz, L. B. (2003). The camptothecins. Lancet, 361, 2235-2242 https://doi.org/10.1016/S0140-6736(03)13780-4
  17. Pratesi, G., Tortoreto, M., Corti, C., Giardini, R. and Zunino, F. (1995). Successful local regional therapy with topotecan of intraperitoneally growing human ovarian carcinoma xenografts. Brit. J. Cancer, 71, 525-528 https://doi.org/10.1038/bjc.1995.104
  18. SAS Institute, Inc, (1997). SAS/STAT Software: Changes and Enhancements Through Release 6.12. SAS Institute, Cary, NC
  19. Slichenmyer, W. J. and Rowinsky, E. K. (1993). The current status of camptothecin analogues as antitumor agents. J. Natl. Cancer Inst., 85, 271-291 https://doi.org/10.1093/jnci/85.4.271
  20. Takimoto, C. H., Wright, J. and Arbuck, S. G. (1998). Clinical applications of the camptothecins. Biochim. Biophys. Acta, 1400, 107-119 https://doi.org/10.1016/S0167-4781(98)00130-4